GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » Altman Z-Score

Replimune Group (Replimune Group) Altman Z-Score

: N/A (As of Today)
View and export this data going back to 2018. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Replimune Group has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Replimune Group's Altman Z-Score or its related term are showing as below:

During the past 7 years, Replimune Group's highest Altman Z-Score was 80.78. The lowest was -1.34. And the median was 18.84.


Replimune Group Altman Z-Score Historical Data

The historical data trend for Replimune Group's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Altman Z-Score
Premium Member Only Premium Member Only 17.28 - - - -

Replimune Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Replimune Group's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replimune Group Altman Z-Score Distribution

For the Biotechnology industry and Healthcare sector, Replimune Group's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Replimune Group's Altman Z-Score falls into.



Replimune Group Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Replimune Group's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.8266+1.4*-1.2126+3.3*-0.3808+0.6*3.538+1.0*0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $532.93 Mil.
Total Current Assets was $479.16 Mil.
Total Current Liabilities was $38.65 Mil.
Retained Earnings was $-646.21 Mil.
Pre-Tax Income was -50.647 + -60.245 + -49.354 + -48.951 = $-209.20 Mil.
Interest Expense was -1.552 + -1.497 + -1.659 + -1.569 = $-6.28 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $394.11 Mil.
Total Liabilities was $111.39 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(479.164 - 38.65)/532.93
=0.8266

X2=Retained Earnings/Total Assets
=-646.207/532.93
=-1.2126

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-209.197 - -6.277)/532.93
=-0.3808

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=394.110/111.393
=3.538

X5=Revenue/Total Assets
=0/532.93
=0

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Replimune Group has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Replimune Group  (NAS:REPL) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Replimune Group Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Replimune Group's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Replimune Group (Replimune Group) Business Description

Traded in Other Exchanges
Address
500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Executives
Christopher Sarchi officer: Chief Commercial Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos officer: Chief Medical Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito officer: Chief Business Officer C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel officer: Chief Commercial Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman officer: Chief Accounting Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke director, 10 percent owner, officer: Executive Chairman C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin director, 10 percent owner, officer: President and C.E.O. C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin 10 percent owner, officer: Chief Operating Officer C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi officer: Chief Financial Officer C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139

Replimune Group (Replimune Group) Headlines

From GuruFocus

Should Investors Worry About Replimune Group Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-20-2023

Replimune Announces Pricing of Public Offering

By GlobeNewswire GlobeNewswire 12-09-2022

Should Investors Worry About Replimune Group Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-19-2023

Replimune Announces Proposed Public Offering

By Value_Insider Value_Insider 12-07-2022

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

By sperokesalga sperokesalga 06-05-2023

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-04-2023